Open Journal Systems

A longitudinal study of outcomes and patterns of failure in postoperative gingivo-buccal oral squamous cell carcinoma treated with concurrent chemotherapy and intensity modulated radiotherapy

Sweta Sharma ()
Tej Prakash Soni ()
Nidhi Patni ()

Abstract


This study aims to determine the outcomes and patterns of failure in gingivo-buccal oral squamous cell carcinoma (OSCC) after postoperative intensity modulated radiotherapy (IMRT) with concurrent chemotherapy. A prospective single-arm study was conducted at our institute from October 2014 to June 2016. Fourty-two patients with postoperative gingivo-buccal OSCC (stage III/IV) intended for curative treatment by IMRT and concurrent chemotherapy were analysed. The median prescribed dose was 60 Gy (range 60–66 Gy). At median follow-up of 12 months, the 1-year loco-regional control (LRC) rate was 95.24%. Two (4.76%) patients experienced recurrence in local and regional areas, respectively. Both the patients showed in-field pattern of recurrence. No marginal or out-of-field recurrence was observed. Four (9.52%) patients failed distantly. The 1-year loco-regional recurrence free survival (LRRFS), distant metastasis free survival (DMFS) and overall survival (OS) estimates were 95.24%, 90.48% and 97.62%, respectively. None of the prognostic factors retained in the model as independent significant predictor for LRRFS, DMFS and OS (p > 0.05) on multivariate analysis. Although increasing age, pT3–4, lymphovascular invasion (LVI), extracapsular extension (ECE), depth of invasion >4 mm, grade 2–3 and ryles tube insertion were associated with higher hazards ratio. Acute grade 2 mucositis and dermatitis toxicity were experienced by 54.76% and 42.86%, respectively. Late grade 2 xerostomia and trismus were experienced by 28.57% and 35.71%, respectively. Improvement in mean quality of life (QOL) score assessed by FACT-HN questionnaires was found to be statistically significant (p < 0.01). IMRT, as an adjuvant treatment, is effective for gingivo-buccal OSCC with acceptable toxicities and also significantly improved mean QOL score over period of time after treatment. Most failures were in-field failures. Further clinical studies are necessary to improve the outcomes of patients with high risk features.

Keywords


head and neck cancer; gingivo-buccal oral cancer; IMRT; outcomes; patterns of failures

Full Text:

PDF

References


Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Can 2010; 127(12): 2893–2917. doi: 10.1002/ijc.25516.

Fang F, Wan Leung S, Huang C, Liu Y, Wang C, et al. Combined-modality therapy for squamous carcinoma of the buccal mucosa: Treatment results and prognostic factors. Head Neck 1997; 19(6): 506–512. doi: 10.1002/(SICI)1097-0347(199709)19:6<506::AID-HED8>3.0.CO;2-2.

Bernier J, Cooper JS, Pajak TF, Van Glabbeke M, Bourhis J, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (95-01). Head Neck 2005; 27(10): 843–850. doi: 10.1002/hed.20279.

Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 2006; 79(1): 15–20. doi: 10.1016/j.radonc.2006.03.009.

Grégoire V. Implementation of intensity-modulated radiation therapy in head and neck tumours: What are the important data for biological optimization? Rays 2004; 29(3): 271–274.

Chui CS, Spirou SV. Inverse planning algorithms for external beam radiation therapy. Med Dosim 2001; 26(2): 189–197. doi: 10.1016/S0958-3947(01)00069-3.

Chui CS, Chan MF, Yorke E, et al. Delivery of intensity-modulated radiation therapy with a conventional multileaf collimator: comparison of dynamic and segmental methods. Med Phys 2001; 28(12): 2441–2449. doi: 10.1118/1.1418018.

Eisbruch A, Kim H, Terrell J, Marsh L, Dawson L, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Bio Phys 2001; 50(3): 695–704. doi: 10.1016/S0360-3016(01)01512-7.

Ship JA. Diagnosing, managing, and preventing salivary gland disorders. Oral Dis 2002; 8(2): 77–89. doi: 10.1034/j.1601-0825.2002.2o837.x.

Graff F, Lapeyre M, Desandes E, Ortholan C, Bensadoun R, et al. The impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancers patients. Matched-pair comparison with conventional radiotherapy. Radiother Oncol 2007; 82: S14. doi: 10.1016/S0167-8140(07)80044-2.

Buettner F, Miah AB, Gulliford SL, Hall E, Harrington KJ, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol 2012; 103(1): 82–87. doi: 10.1016/j.radonc.2012.02.006.

Van der Laan H, Christianen M, Bijl H, Schilstra C, Langendijk JA. The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: An in silico planning comparative study. Radiother Oncol 2012; 103(1): 76–81. doi: 10.1016/j.radonc.2011.11.001.

Mendenhall WM, Mancuso AA. Radiotherapy for head and neck cancer: Is the “next level” down? Int J Radiat Oncol Biol Phys 2009; 73(3): 645–646. doi: 10.1016/j.ijrobp.2008.08.061.

Harari PM. Beware the swing and a miss: Baseball precautions for conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70(3): 657–659. doi: 10.1016/j.ijrobp.2007.10.065.

Lee WR. Technology assessment: Vigilance required. Int J Radiat Oncol Biol Phys 2008;70(3): 652–653. doi: 10.1016/j.ijrobp.2007.09.030.

Chen A, Farwell D, Luu Q, Chen L, Vijayakumar S, et al. Marginal Misses After Postoperative Intensity-Modulated Radiotherapy for Head and Neck Cancer. Int J Radiat Oncol Bio Phys 2011; 80(5): 1423–1429. doi: 10.1016/j.ijrobp.2010.04.011.

Chen A, Farwell D, Luu Q, Chen L, Vijayakumar S, et al. Misses and near-misses after postoperative radiation therapy for head and neck cancer: Comparison of IMRT and non-IMRT techniques in the CT-simulation era. Head Neck 2010; 32(11):1452–1459. doi: 10.1002/hed.21343.

Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT): Contents. J ICRU 2010; 10(1): NP. doi: 10.1093/jicru/ndq002.

Grégoire V, Levendag P, Ang K, Bernier J, Braaksma M, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003; 69(3): 227–236. doi: 10.1016/j.radonc.2003.09.011.

Commowick O, Grégoire V, Malandain G. Atlas-based delineation of lymph node levels in head and neck computed tomography images. Radiother Oncol 2008; 87(2): 281–289. doi: 10.1016/j.radonc.2008.01.018.

Lee N, Lu J. Target volume delineation and field setup. Berlin: Springer 2013. doi: 10.1007/978-3-642-28860-9.

Bentzen S, Constine L, Deasy J, Eisbruch A, Jackson A, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An introduction to the scientific issues. Int J Radiat Oncol Bio Phys 2010; 76(3): S3–S9. doi: 10.1016/j.ijrobp.2009.09.040.

Chao KS, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head and neck cancer. Int J Radiat Oncol Biol Phys 2003; 55(2): 312–321. doi: 10.1016/S0360-3016(02)03940-8.

Yao M, Chang K, Funk G, Lu H, Tan H, et al. The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy—the University of Iowa Experience. Int J Radiat Oncol Bio Phys 2007; 67(5): 1332–1341. doi: 10.1016/j.ijrobp.2006.11.030.

Hsieh C, Shueng P, Wang L, Liao L, Lin Y, et al. Clinical effectiveness, toxicity, and failure patterns of helical tomotherapy for postoperative oral cavity cancer patients. Onco Targets Ther 2014; 7: 405–414. doi: 10.2147/OTT.S59998.

Chen A, Farwell D, Luu Q, Chen L, Vijayakumar S, et al. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Bio Phys 2011; 80(5): 1423–1429. doi: 10.1016/j.ijrobp.2010.04.011.

Studer G, Zwahlen R, Graetz K, Davis B, Glanzmann C. IMRT in oral cavity cancer. Radiat Oncol 2007; 2(1):16. doi: 10.1186/1748-717X-2-16.

Chan A, Huang S, Le L, Yu E, Dawson L, et al. Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failures. Oral Oncol 2013; 49(3): 255–260. doi: 10.1016/j.oraloncology.2012.09.006.

Gomez D, Zhung J, Gomez J, Chan K, Wu A, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J of Radiat Oncol Bio Phys 2009; 73(4): 1096–1103. doi: 10.1016/j.ijrobp.2008.05.024.

Daly M, Le Q, Kozak M, Maxim P, Murphy J, et al. Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: Patterns of failure and predictors of local control. Int J Radiat Oncol Bio Phys 2011; 80(5): 1412–1422. doi: 10.1016/j.ijrobp.2010.04.031.

Sher D, Thotakura V, Balboni T, Norris C, Haddad R, et al. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Bio Phys 2011; 81(4): e215–e222. doi: 10.1016/j.ijrobp.2011.02.023.

Parsons J, Mendenhall W, Stringer S, Cassisi N, Million R. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Bio Phys 1997; 39(1): 137–148. doi: 10.1016/S0360-3016(97)00152-1.

Zelefsky M, Harrison L, Fass D, Armstrong J, Spiro R, et al. Postoperative radiotherapy for oral cavity cancers: Impact of anatomic subsite on treatment outcome. Head Neck 1990; 12(6): 470–475. doi: 10.1002/hed.2880120604.

Geretschläger A, Bojaxhiu B, Crowe S, Arnold A, Manser P, et al. Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. Radiat Oncol 2012; 7(1): 175. doi: 10.1186/1748-717X-7-175.

Liao C, Lin C, Fan K, Wang H, Ng S, et al. Identification of a high-risk group among patients with oral cavity squamous cell carcinoma and pT1–2N0 disease. Int J Radiat Oncol Bio Phys 2012; 82(1): 284–290. doi: 10.1016/j.ijrobp.2010.09.036.

Tan W, Chia C, Tan H, Soo K, Iyer N. Prognostic Significance of Invasion Depth in Oral Tongue Squamous Cell Carcinoma. ORL J Otorhinolaryngol Relat Spec 2012; 74(5): 264–270. doi: 10.1159/000343796.

Ghoshal S, Mallick I, Panda N, Sharma S. Carcinoma of the buccal mucosa: Analysis of clinical presentation, outcome and prognostic factors. Oral Oncol 2006; 42(5):533–539. doi: 10.1016/j.oraloncology.2005.10.005.

Fang F, Wan Leung S, Huang C, Liu Y, Wang C, et al. Combined‐modality therapy for squamous carcinoma of the buccal mucosa: Treatment results and prognostic factors. Head Neck 1997; 19(6): 506–512.

Koukourakis M, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head–neck cancer. Br J Cancer 2012; 106(5): 846–853. doi: 10.1038/bjc.2012.33.

Bittner M, Grosu A. Hypoxia in head and neck tumors: Characteristics and development during therapy. Front Oncol 2013; 3: 223. doi: 10.3389/fonc.2013.00223.



DOI: http://dx.doi.org/10.30564/amor.v3i6.142

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Sweta Sharma, Tej Prakash Soni, Nidhi Patni

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.